Parisa Shamsesfandabadi | Radiation oncology | Best Researcher Award

Dr. Parisa Shamsesfandabadi | Radiation oncology | Best Researcher Award

Dr. Parisa Shamsesfandabadi ๐Ÿ‡บ๐Ÿ‡ธ is a passionate radiation oncologist with a dynamic academic and clinical background, currently serving as Chief Resident at Allegheny Health Network in Pittsburgh, PA ๐Ÿ’ผ. She combines a global medical foundation from Iran with extensive U.S. clinical training ๐Ÿ‡ฎ๐Ÿ‡ทโžก๏ธ๐Ÿ‡บ๐Ÿ‡ธ. Driven by innovation and compassion, Parisa has earned national recognition with multiple prestigious awards ๐Ÿ…. Her dedication extends beyond clinical excellence to impactful research, global health, and mentorship ๐ŸŒ๐Ÿ“š. With hands-on experiences at leading institutions like Duke, UNC, and VA Medical Center, her expertise spans brain, breast, liver, and prostate cancer research ๐Ÿง ๐Ÿ’ช. Parisaโ€™s unique blend of research, service, and leadership reflects her lifelong commitment to patient care, academic excellence, and transformative cancer therapy ๐ŸŒŸ. In addition to her clinical role, she actively contributes as an editorial assistant, social ambassador, and peer-reviewer to renowned medical journals and organizations ๐Ÿ“–๐Ÿค. She’s a true rising star in oncology ๐Ÿš€.

Profile

Education ๐ŸŽ“

๐Ÿ“ Chief Resident, Radiation Oncology โ€“ Allegheny Health Network, PA (2024โ€“Present) ๐Ÿ‘ฉโ€โš•๏ธ
๐Ÿ“ Residency, Radiation Oncology โ€“ Allegheny Health Network, PA (2019โ€“2024) ๐Ÿ’‰
๐Ÿ“ Internship (PGY-1), Transitional Year โ€“ Southern Hills Hospital, Las Vegas, NV (2019โ€“2020) ๐Ÿฅ
๐Ÿ“ M.D. โ€“ Kashan University of Medical Sciences, Iran (2007โ€“2014) ๐ŸŽ“๐Ÿ‡ฎ๐Ÿ‡ท
๐Ÿ“ High School โ€“ Tehran Farzanegan School, NODET (2000โ€“2007) ๐Ÿง ๐Ÿซ
Parisa’s academic journey reflects brilliance from the start, attending Iranโ€™s elite NODET school ๐ŸŒŸ. She pursued medicine at KaUMS, consistently ranking top in medical Olympiads ๐Ÿฅ‡. Her U.S. medical training includes internship and residency in highly reputed institutions, leading to her current leadership as Chief Resident ๐Ÿง‘โ€โš•๏ธ. Her academic record is peppered with awards, research, and international training, preparing her for a successful future as a physician-scientist and leader in cancer care ๐Ÿงฌ๐Ÿฉบ.

Experience ๐Ÿ‘จโ€๐Ÿซ

๐Ÿ“ Chief Resident, Radiation Oncology โ€“ AHN (2024โ€“Present)
๐Ÿ“ Research Associate โ€“ VA Medical Center, Durham, NC ๐Ÿงช
๐Ÿ“ Visiting Scholar โ€“ Duke, UNC, CCC Las Vegas ๐Ÿซ
๐Ÿ“ Research Visitor โ€“ RAI Lab, Duke University (Glioma Imaging) ๐Ÿง 
๐Ÿ“ Research Associate โ€“ KaUMS, Iran (Probiotics Study) ๐Ÿงƒ
๐Ÿ“ Medical Assistant โ€“ Advanced Pain Management, NV ๐Ÿ’Š
๐Ÿ“ Volunteer โ€“ Rural Clinics, Pediatrics & Geriatrics Programs ๐Ÿง’๐Ÿ‘ต
๐Ÿ“ Editorial Assistant โ€“ eContour ๐Ÿ“˜
๐Ÿ“ Communications Intern โ€“ RTOG Foundation ๐Ÿ’ฌ
Dr. Parisa brings a rich portfolio of clinical and research experience across top U.S. and international institutions ๐ŸŒ. From clinical research on prostate and brain cancers to hands-on patient care and administrative duties, she is known for her leadership, empathy, and academic dedication ๐Ÿฅ๐Ÿง ๐Ÿ“Š.

Awards & Recognitions ๐Ÿ…

๐ŸŽ– 2024 RTOG Communications Intern
๐Ÿ’ฐ 2023 $25K Grant โ€“ MRLinac Sarcoma (Benedum Foundation)
๐Ÿงณ 2023 Travel Grants โ€“ ARS, ACRO, ACR
๐Ÿฅ‡ 2022 Resident Best Abstract โ€“ ABS
๐ŸŽ– 2022 Editorial/Fellow Roles โ€“ eContour, The Mednet, NRG
๐ŸŒŸ 2022 RePRT Peer Reviewer โ€“ Red Journal
๐Ÿ† 2022 Travel Award โ€“ eContour Vulvar Cancer Guidelines
๐Ÿ‘ฉโ€๐ŸŽ“ Olympiad Champion โ€“ 4x Gold in Iran Medical Olympiads
๐Ÿง  UNESCO Youth Award โ€“ Earthquake Awareness Project
๐Ÿ… Sharif University Medal โ€“ Math & Graphs Competition
๐Ÿงช Ranked 1st in Nationwide Chemistry Lab Exam
๐Ÿ“• Published Short Book โ€“ โ€œWorld of Animalsโ€
๐Ÿ“š Parisaโ€™s excellence is recognized through national and international grants, editorial roles, peer-review selections, and top medical student honors ๐Ÿ…. From early academic brilliance to clinical and research impact, her accolades reflect a rare blend of intellect, service, and innovation ๐ŸŒโœจ.

Research Interests ๐Ÿ”ฌ

๐Ÿง  Radiogenomics โ€“ Brain Cancer Imaging (Duke, UNC)
๐Ÿงฌ MR-Linac SBRT โ€“ Liver, Pancreatic, Prostate, and Breast Cancers
๐Ÿ’ช Strength Training Impact โ€“ Radiotherapy in Breast Cancer
๐Ÿงฒ Adaptive Radiation Therapy โ€“ CBCT, MRI-based Comparisons
๐Ÿ” Treatment Planning โ€“ Monte Carlo vs Cone Algorithm
๐Ÿงซ Biomarker Evaluation โ€“ Breast Cancer (KaUMS & Leiden University)
๐Ÿงƒ Probiotics vs Regular Yogurt in Pediatric Diarrhea
๐Ÿ–ฅ Editorial & Peer Review Roles โ€“ Red Journal, The Mednet, eContour
Dr. Shamsesfandabadiโ€™s research bridges advanced imaging, functional planning, and personalized therapy in oncology ๐Ÿง . Her projects focus on enhancing precision radiation therapy using radiogenomics, AI-driven adaptive planning, and improving survivorship through integrative approaches ๐Ÿ’ป๐Ÿ’ก. Sheโ€™s driven to optimize outcomes in patients with complex cancers like gliomas, HCC, and pancreatic malignancies, while actively contributing to guidelines and clinical trials ๐Ÿงช๐Ÿ’ฅ. A rising voice in the next-gen of physician-scientists ๐ŸŒŸ.

Publicationsย 
  • -Kirichenko, A., Uemura, T., Hasan, S., Lian, Y., Abel, S., Renz, P.,
    Shamsesfandabadi, P., Carpenter, J., Thai, N., โ€œStereotactic Body Radiotherapy
    (SBRT) for Hepatocellular Carcinoma (HCC) with Single Photon Emission
    Computed Tomography (SPECT) Functional Treatment Planning in Patients with
    Advanced Hepatic Cirrhosis.โ€ Advances in Radiation Oncology (Accepted,
    July 2023).
  • Goss, M., Champ, C., Trombetta, M, Shamsesfandabadi, P., DeMartino, V.,
    Wegner, R., Beriwal, S., Eisen, V. โ€œThe Comparison of Collapsed Cone and
    Monte Carlo Algorithms in Tangential Breast Planning.โ€ Journal of Radiotherapy
    in Practice. (April 2023).
  • Mazurowski, M.A., Clark, K., Czarnek, N. M., Shamsesfandabadi, P., et al.
    โ€œRadiogenomics of lower-grade glioma: algorithmically assessed tumor shape
    is associated with tumor genomic subtypes in a multi-institutional study with
    The Cancer Genome Atlas data.โ€ Journal of Neuro-Oncology. 2017, May;
    133(1): 27-35. Cited in PubMed; PMID: 28470431.
  • Mazurowski, M. A., Clark, K., Czarnek, N. M., Shamsesfandabadi, P., et al.
    (2017, March 21). โ€œRadiogenomic analysis of lower grade glioma: a pilot multiinstitutional study shows an association between quantitative image features
    and tumor genomics.โ€ SPIE, The international society for optics and photonics.
  • – Sharif, A., Kheirkhah, D., Shamsesfandabadi, P., et al. โ€œComparison of Regular
    and Probiotic Yogurts in Treatment of Acute Watery Diarrhea in Children.โ€
    Journal of Probiotics and Health. 2016, Feb; 5(1): 164.

Natalia Baran | Cancer Research | Best Researcher Award

Assist. Prof. Dr. Natalia Baran | Cancer Research | Best Researcher Award

Leading Attending at InselSpital Bern, Switzerland.

Dr. Natalia Baran is an Assistant Professor in the Department of Leukemia at MD Anderson Cancer Center, where she focuses on developing novel therapeutic strategies targeting metabolic vulnerabilities in leukemia. Her expertise lies in understanding how metabolic reprogramming can lead to drug resistance and contribute to leukemia progression. With a medical background and extensive experience in both clinical and research settings, Dr. Baran has been at the forefront of studies that aim to modulate metabolic pathways to enhance anti-leukemic responses. By combining insights from molecular biology, immunology, and clinical practice, she is actively working toward discovering innovative treatments for leukemia. Dr. Baranโ€™s research holds great promise in advancing leukemia therapy, particularly by targeting metabolic reprogramming in the context of therapy resistance. Her multidisciplinary approach, integrating clinical data with laboratory research, makes her a key figure in leukemia research.

Profile

Scopus

Google Scholar

Orcid

Education:

Dr. Natalia Baran completed her undergraduate studies in Biotechnology, earning a Master of Science degree in 2006 from Wroclaw University of Science and Technology in Poland. She further pursued medical education and obtained her Medical Doctor (MD) degree from Wroclaw Medical University in 2007. Driven by her passion for research, Dr. Baran earned a Ph.D. in Medicine from the University of Bonn in 2015. Her doctoral research laid the foundation for her current focus on leukemia and metabolic reprogramming. In addition, Dr. Baran underwent extensive postdoctoral training at MD Anderson Cancer Center, where she honed her expertise in hematology and oncology, contributing significantly to translational research in leukemia. Her diverse educational background, blending science and medicine, has shaped her comprehensive approach to cancer research.

Professional Experience:

Dr. Baran has a rich professional experience that bridges clinical practice and cutting-edge research. After completing her MD, she pursued clinical residencies in Internal Medicine, Hematology, and Oncology at prestigious German institutions, including the University of Heidelberg and the University of Bonn. This clinical experience laid the groundwork for her subsequent focus on leukemia research. In 2016, she joined MD Anderson Cancer Center as a Postdoctoral Fellow in the Department of Leukemia. During her postdoctoral tenure, Dr. Baran worked closely with Dr. Marina Konopleva, exploring the role of metabolic pathways in leukemia resistance. By 2022, she had transitioned to an Assistant Professor role, continuing her translational research in leukemia, with a particular emphasis on identifying novel therapeutic strategies. Her clinical and research experiences synergize to enhance her contributions to the leukemia research community.

Research Interests:

Dr. Baran’s research is primarily centered on exploring metabolic vulnerabilities and their role in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Her work seeks to understand the mechanisms through which metabolic reprogramming in leukemia cells contributes to drug resistance and tumor progression. Dr. Baran is particularly interested in how modulating the metabolic environment can enhance the effectiveness of leukemia therapies. By focusing on the interplay between metabolism and leukemic cell survival, she aims to identify new therapeutic strategies that target metabolic pathways to overcome resistance to traditional treatments. Her research also explores how immune modulation can be integrated with metabolic interventions to develop more efficient leukemia therapies.

Awards and Honors:

Dr. Baran has received recognition for her contributions to leukemia research, although specific awards are not detailed in available sources. However, her research has been featured prominently in major scientific forums, including the Annual Metabolism in Cancer Symposium organized by MD Anderson. Her work has earned her respect within the scientific community, as evidenced by her continued role as an Assistant Professor and her involvement in prestigious cancer research initiatives. Dr. Baranโ€™s impact is evident in her ongoing efforts to bridge the gap between basic science and clinical application, aiming to revolutionize leukemia treatment.

Skills:

Dr. Baran’s research skills encompass a wide range of techniques in molecular biology, cell culture, and metabolic analysis. She is highly proficient in studying the metabolic pathways that drive leukemia, using state-of-the-art technologies such as high-resolution metabolic flux analysis, RNA sequencing, and advanced cell imaging. Dr. Baran is skilled at integrating basic science with clinical data, ensuring that her research translates into practical therapeutic interventions. Her expertise in immunology further complements her research in leukemia, allowing her to investigate the potential of combining metabolic therapies with immune modulation to improve patient outcomes. Her interdisciplinary approach is a key strength in her ongoing work in leukemia research.

Publication Top Notes

A Selective BCL-XL PROTAC Degrader Achieves Safe and Potent Antitumor Activity

  • Authors: S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang, X Liu, D Thummuri, et al.
  • Journal: Nature Medicine
  • Volume: 25(12), Pages 1938โ€“1947
  • Cited by: 515
  • Year: 2019

Targeting a Cytokine Checkpoint Enhances the Fitness of Armored Cord Blood CAR-NK Cells

  • Authors: M Daher, R Basar, E Gokdemir, N Baran, N Uprety, AK Nunez Cortes, et al.
  • Journal: Blood, The Journal of the American Society of Hematology
  • Volume: 137(5), Pages 624โ€“636
  • Cited by: 226
  • Year: 2021

Inhibiting Glutaminase in Acute Myeloid Leukemia: Metabolic Dependency of Selected AML Subtypes

  • Authors: P Matre, J Velez, R Jacamo, Y Qi, X Su, T Cai, SM Chan, A Lodi, et al.
  • Journal: Oncotarget
  • Volume: 7(48), Pages 79722
  • Cited by: 194
  • Year: 2016

Complex I Inhibitor of Oxidative Phosphorylation in Advanced Solid Tumors and Acute Myeloid Leukemia: Phase I Trials

  • Authors: TA Yap, N Daver, M Mahendra, J Zhang, C Kamiya-Matsuoka, et al.
  • Journal: Nature Medicine
  • Volume: 29(1), Pages 115โ€“126
  • Cited by: 182
  • Year: 2023

Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy

  • Authors: N Baran, M Konopleva
  • Journal: Clinical Cancer Research
  • Volume: 23(10), Pages 2382โ€“2390
  • Cited by: 126
  • Year: 2017

Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Bloodโ€“Derived NK Cells Facilitates CAR-Like Responses Against CD30+ Malignancies

  • Authors: LN Kerbauy, ND Marin, M Kaplan, PP Banerjee, MM Berrien-Elliott, et al.
  • Journal: Clinical Cancer Research
  • Volume: 27(13), Pages 3744โ€“3756
  • Cited by: 117
  • Year: 2021

Clonal Selection and Therapy Resistance in Acute Leukemias: Mathematical Modelling Explains Different Proliferation Patterns at Diagnosis and Relapse

  • Authors: T Stiehl, N Baran, AD Ho, A Marciniak-Czochra
  • Journal: Journal of The Royal Society Interface
  • Volume: 11(94), Article ID 20140079
  • Cited by: 106
  • Year: 2014

Activation of RAS/MAPK Pathway Confers MCL-1 Mediated Acquired Resistance to BCL-2 Inhibitor Venetoclax in Acute Myeloid Leukemia

  • Authors: Q Zhang, B Riley-Gillis, L Han, Y Jia, A Lodi, H Zhang, S Ganesan, R Pan, et al.
  • Journal: Signal Transduction and Targeted Therapy
  • Volume: 7(1), Article ID 51
  • Cited by: 104
  • Year: 2022

Conclusion:

Dr. Natalia Baran is a prominent researcher whose work in leukemia has the potential to transform therapeutic approaches, especially through targeting metabolic pathways. Her strong academic background, combined with extensive clinical and research experience, enables her to address one of the most pressing challenges in leukemia treatment: drug resistance. By focusing on metabolic reprogramming, Dr. Baran is paving the way for innovative strategies to combat leukemia and improve patient outcomes. Her expertise in integrating basic research with clinical applications ensures that her contributions will have a lasting impact on the field of oncology, particularly in the development of new, more effective therapies for leukemia.